Description
An inhibitor of PDE4 (IC50s = 54, 65, 239, and 166 nM for PDE4A-D, respectively); selective for PDE4 over PDE1, PDE7A, PDE7B, and PDE9A (IC50 = ≥10,000 nM for all) but does inhibit PDE3A, PDE3B, and PDE5A (IC50s = 1,600, 2,700, and 3,510 nM, respectively); inhibits LPS-induced production of TNF-α and fMLP-induced production of LTB4 in isolated human whole blood (IC50s = 6.2 and 2.5 μM, respectively); inhibits bronchospasm by 34% in a guinea pig model of leukotriene-mediated allergic bronchospasm at 5 mg/kg; prevents increases in TNF-α, IL-1β, and IL-6 expression in the striatum in a mouse model of MPTP-induced Parkinson’s disease; increases striatal expression of GDNF in MPTP-treated and -untreated mice when at 40 and 50 mg/kg, respectively, twice per day
Formal name: 2-methyl-1-[2-(1-methylethyl)pyrazolo[1,5-a]pyridin-3-yl]-1-propanone
Synonyms: AV 411|KC-404
Molecular weight: 230.3
CAS: 50847-11-5
Purity: ≥98%
Formulation: A crystalline solid
Product Type|Biochemicals|Small Molecule Inhibitors|Phosphodiesterases||Research Area|Cell Biology|Cell Signaling|cAMP Signaling||Research Area|Cell Biology|Cell Signaling|cGMP Signaling||Research Area|Immunology & Inflammation|Inflammatory Lipid Mediators|Leukotrienes||Research Area|Immunology & Inflammation|Pulmonary Diseases|Asthma||Research Area|Neuroscience|Neurodegenerative Disorders|Parkinson’s Disease